Physician profile
Robert G Stepp
NPI 1417917113
$7,214.98
in general payments reported to CMS, 2019-2025
46 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $466 · 2021: $667 · 2022: $628 · 2023: $1,464 · 2024: $728 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $793.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $593.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $592.26 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $581.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.33 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $487.79 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $467.91 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.44 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $310.94 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Amgen INC. | $267.93 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $256.07 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $194.21 | 2019-2021 | |
| Astellas Pharma US INC | $180.28 | 2019-2024 | Veozah, Myrbetriq |
| Scilex Pharmaceuticals INC. | $143.77 | 2021-2024 | Ztlido |
| Bayer Healthcare Pharmaceuticals INC. | $111.44 | 2021-2025 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $110.70 | 2025 | Sunosi, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $99.72 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.73 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $88.02 | 2019-2021 | |
| Allergan, INC. | $81.94 | 2019-2021 | |
| Exact Sciences Corporation | $73.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Upsher-Smith Laboratories LLC | $61.21 | 2019-2021 | |
| Dexcom, INC. | $57.36 | 2021-2023 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $50.54 | 2019-2025 | Austedo Xr |
| Sumitomo Pharma America, INC. | $49.25 | 2024-2025 | Gemtesa |
| Bausch Health US, LLC | $47.87 | 2023-2024 | Aplenzin, Wellbutrin |
| Boston Scientific Corporation | $46.38 | 2025 | General - Biliary Devices |
| Ultragenyx Pharmaceutical INC. | $36.72 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $35.03 | 2025 | Voquezna |
| Jazz Pharmaceuticals INC. | $31.12 | 2021 | |
| Eisai INC. | $30.14 | 2019-2020 | |
| Nevro Corp. | $27.83 | 2023 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.32 | 2025 | Caplyta |
| Saluda Medical Americas, INC. | $23.89 | 2023 | Evoke Scs |
| Medtronic, INC. | $23.48 | 2025 | Intellis Adaptivestim |
| Inspire Medical Systems, INC. | $22.10 | 2025 | Inspire |
| Lundbeck LLC | $21.89 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $21.30 | 2025 | Nexletol |
| Harmony Biosciences LLC | $21.19 | 2023 | Wakix |
| Antares Pharma, INC. | $18.00 | 2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $17.92 | 2025 | Quviviq |
| Ardelyx, INC. | $16.16 | 2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.20 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.87 | 2020 | |
| Horizon Therapeutics Plc | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.